Cancer-associated fibroblasts: a versatile mediator in tumor progression, metastasis, and targeted therapy

1.

Bussard, K. M., Mutkus, L., Stumpf, K., Gomez-Manzano, C., & Marini, F. C. (2016). Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Research: BCR, 18(1), 84. https://doi.org/10.1186/s13058-016-0740-2CrossRefPubMedPubMedCentral

2.

Rahmanian, M., Seyfoori, A., Ghasemi, M., Shamsi, M., Kolahchi, A. R., Modarres, H. P. ,…, Majidzadeh-A, K. (2021). In-vitro tumor microenvironment models containing physical and biological barriers for modelling multidrug resistance mechanisms and multidrug delivery strategies. Journal of Controlled Release: Official Journal of the Controlled Release Society, 334, 164–177. https://doi.org/10.1016/j.jconrel.2021.04.024

3.

Marozzi, M., Parnigoni, A., Negri, A., Viola, M., Vigetti, D., Passi, A. ,…, Rizzi, F. (2021). Inflammation, extracellular matrix remodeling, and proteostasis in tumor microenvironment. International Journal of Molecular Sciences, 22(15), 8102. https://doi.org/10.3390/ijms22158102

4.

Hu, D., Li, Z., Zheng, B., Lin, X., Pan, Y., Gong, P. ,…, Wang, L. (2022). Cancer-associated fibroblasts in breast cancer: Challenges and opportunities. Cancer Communications (London, England), 42(5), 401–434. https://doi.org/10.1002/cac2.12291

5.

Bartoschek, M., Oskolkov, N., Bocci, M., Lövrot, J., Larsson, C., Sommarin, M. ,…, Pietras, K. (2018). Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nature Communications, 9(1), 5150. https://doi.org/10.1038/s41467-018-07582-3

6.

Bryce, A. S., Dreyer, S. B., Froeling, F. E. M., & Chang, D. K. (2022). Exploring the biology of cancer-associated fibroblasts in pancreatic cancer. Cancers, 14(21), 5302. https://doi.org/10.3390/cancers14215302CrossRefPubMedPubMedCentral

7.

Montori, M., Scorzoni, C., Argenziano, M. E., Balducci, D., De Blasio, F., Martini, F. ,…, Maroni, L. (2022). Cancer-associated fibroblasts in cholangiocarcinoma: Current knowledge and possible implications for therapy. Journal of Clinical Medicine, 11(21), 6498. https://doi.org/10.3390/jcm11216498

8.

Wan, P.K.-T., Ryan, A. J., & Seymour, L. W. (2021). Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus. Molecular Therapy: The Journal of the American Society of Gene Therapy, 29(5), 1668–1682. https://doi.org/10.1016/j.ymthe.2021.04.015CrossRefPubMed

9.

Prasad, V., Fojo, T., & Brada, M. (2016). Precision oncology: Origins, optimism, and potential. The Lancet. Oncology, 17(2), e81–e86. https://doi.org/10.1016/S1470-2045(15)00620-8CrossRefPubMed

10.

Kalluri, R., & Zeisberg, M. (2006). Fibroblasts in cancer. Nature Reviews Cancer, 6(5), 392–401. https://doi.org/10.1038/nrc1877CrossRefPubMed

11.

Kalluri, R. (2016). The biology and function of fibroblasts in cancer. Nature Reviews. Cancer, 16(9), 582–598. https://doi.org/10.1038/nrc.2016.73CrossRefPubMed

12.

Kennel, K. B., Bozlar, M., De Valk, A. F., & Greten, F. R. (2022). Cancer-associated fibroblasts in inflammation and anti-tumor immunity. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, CCR-22–1031. https://doi.org/10.1158/1078-0432.CCR-22-1031

13.

Shi, X., Young, C. D., Zhou, H., & Wang, X. (2020). Transforming growth factor-β signaling in fibrotic diseases and cancer-associated fibroblasts. Biomolecules, 10(12), 1666. https://doi.org/10.3390/biom10121666CrossRefPubMedPubMedCentral

14.

Kuzet, S.-E., & Gaggioli, C. (2016). Fibroblast activation in cancer: When seed fertilizes soil. Cell and Tissue Research, 365(3), 607–619. https://doi.org/10.1007/s00441-016-2467-xCrossRefPubMed

15.

Li, Z., Low, V., Luga, V., Sun, J., Earlie, E., Parang, B. ,…, Blenis, J. (2022). Tumor-produced and aging-associated oncometabolite methylmalonic acid promotes cancer-associated fibroblast activation to drive metastatic progression. Nature Communications, 13(1), 6239. https://doi.org/10.1038/s41467-022-33862-0

16.

Fang, T., Lv, H., Lv, G., Li, T., Wang, C., Han, Q. ,…, Wang, H. (2018). Tumor-derived exosomal miR-1247–3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. Nature Communications, 9(1), 191. https://doi.org/10.1038/s41467-017-02583-0

17.

Ammirante, M., Shalapour, S., Kang, Y., Jamieson, C. A. M., & Karin, M. (2014). Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts. Proceedings of the National Academy of Sciences of the United States of America, 111(41), 14776–14781. https://doi.org/10.1073/pnas.1416498111CrossRefPubMedPubMedCentral

18.

Kalluri, R., & Weinberg, R. A. (2009). The basics of epithelial-mesenchymal transition. The Journal of Clinical Investigation, 119(6), 1420–1428. https://doi.org/10.1172/JCI39104CrossRefPubMedPubMedCentral

19.

Marconi, G. D., Fonticoli, L., Rajan, T. S., Pierdomenico, S. D., Trubiani, O., Pizzicannella, J., & Diomede, F. (2021). Epithelial-mesenchymal transition (EMT): The type-2 EMT in wound healing, tissue regeneration and organ fibrosis. Cells, 10(7), 1587. https://doi.org/10.3390/cells10071587CrossRefPubMedPubMedCentral

20.

Brabletz, T., Kalluri, R., Nieto, M. A., & Weinberg, R. A. (2018). EMT in cancer. Nature Reviews. Cancer, 18(2), 128–134. https://doi.org/10.1038/nrc.2017.118CrossRefPubMed

21.

Ang, H. L., Mohan, C. D., Shanmugam, M. K., Leong, H. C., Makvandi, P., Rangappa, K. S. ,…, Sethi, G. (2023). Mechanism of epithelial-mesenchymal transition in cancer and its regulation by natural compounds. Medicinal Research Reviews, 43(4), 1141–1200. https://doi.org/10.1002/med.21948

22.

Toledo, B., Picon-Ruiz, M., Marchal, J. A., & Perán, M. (2022). Dual role of fibroblasts educated by tumour in cancer behavior and therapeutic perspectives. International Journal of Molecular Sciences, 23(24), 15576. https://doi.org/10.3390/ijms232415576CrossRefPubMedPubMedCentral

23.

Adjuto-Saccone, M., Soubeyran, P., Garcia, J., Audebert, S., Camoin, L., Rubis, M. ,…, Tournaire, R. (2021). TNF-α induces endothelial-mesenchymal transition promoting stromal development of pancreatic adenocarcinoma. Cell Death & Disease, 12(7), 649. https://doi.org/10.1038/s41419-021-03920-4

24.

Potenta, S., Zeisberg, E., & Kalluri, R. (2008). The role of endothelial-to-mesenchymal transition in cancer progression. British Journal of Cancer, 99(9), 1375–1379. https://doi.org/10.1038/sj.bjc.6604662CrossRefPubMedPubMedCentral

25.

Pérez, L., Muñoz-Durango, N., Riedel, C. A., Echeverría, C., Kalergis, A. M., Cabello-Verrugio, C., & Simon, F. (2017). Endothelial-to-mesenchymal transition: Cytokine-mediated pathways that determine endothelial fibrosis under inflammatory conditions. Cytokine & Growth Factor Reviews, 33, 41–54. https://doi.org/10.1016/j.cytogfr.2016.09.002CrossRef

26.

Choi, J., Cha, Y. J., & Koo, J. S. (2018). Adipocyte biology in breast cancer: From silent bystander to active facilitator. Progress in Lipid Research, 69, 11–20. https://doi.org/10.1016/j.plipres.2017.11.002CrossRefPubMed

27.

Bochet, L., Lehuédé, C., Dauvillier, S., Wang, Y. Y., Dirat, B., Laurent, V. ,…, Muller, C. (2013). Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer. Cancer Research, 73(18), 5657–5668. https://doi.org/10.1158/0008-5472.CAN-13-0530

28.

Iyoshi, S., Yoshihara, M., Nakamura, K., Sugiyama, M., Koya, Y., Kitami, K. ,…, Kajiyama, H. (2021). Pro-tumoral behavior of omental adipocyte-derived fibroblasts in tumor microenvironment at the metastatic site of ovarian cancer. International Journal of Cancer, 149(11), 1961–1972. https://doi.org/10.1002/ijc.33770

29.

Teichert, M., Milde, L., Holm, A., Stanicek, L., Gengenbacher, N., Savant, S. ,…, Augustin, H. G. (2017). Pericyte-expressed Tie2 controls angiogenesis and vessel maturation. Nature Communications, 8, 16106. https://doi.org/10.1038/ncomms16106

30.

Yao, F., Luo, Y., Liu, Y.-C., Chen, Y.-H., Li, Y.-T., Hu, X.-Y. ,…, Jing, J.-H. (2022). Imatinib inhibits pericyte-fibroblast transition and inflammation and promotes axon regeneration by blocking the PDGF-BB/PDGFRβ pathway in spinal cord injury. Inflammation and Regeneration, 42(1), 44. https://doi.org/10.1186/s41232-022-00223-9

31.

Hosaka, K., Yang, Y., Seki, T., Fischer, C., Dubey, O., Fredlund, E. ,…, Cao, Y. (2016). Pericyte-fibroblast transition promotes tumor growth and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 113(38), E5618–5627. https://doi.org/10.1073/pnas.1608384113

32.

Tang, P. C.-T., Chung, J. Y.-F., Xue, V. W.-W., Xiao, J., Meng, X.-M., Huang, X.-R. ,…, Lan, H.-Y. (2022). Smad3 promotes cancer-associated fibroblasts generation via macrophage-myofibroblast transition. Advanced Science (Weinheim, Baden-Wurttemberg, Germany), 9(1), e2101235. https://doi.org/10.1002/advs.202101235

33.

Huang, H., Wang, Z., Zhang, Y., Pradhan, R. N., Ganguly, D., Chandra, R. ,…, Brekken, R. A. (2022). Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell, 40(6), 656–673.e7. https://doi.org/10.1016/j.ccell.2022.04.011

34.

Biffi, G., & Tuveson, D. A. (2021). Diversity and biology of cancer-associated fibroblasts. Physiological Reviews, 101(1), 147–176. https://doi.org/10.1152/physrev.00048.2019CrossRefPubMed

35.

Rimal, R., Desai, P., Daware, R., Hosseinnejad, A., Prakash, J., Lammers, T., & Singh, S. (2022). Cancer-associated fibroblasts: Origin, function, imaging, and therapeutic targeting. Advanced Drug Delivery Reviews, 189, 114504. https://doi.org/10.1016/j.addr.2022.114504CrossRefPubMed

36.

Kim, D., Kim, J. S., Cheon, I., Kim, S. R., Chun, S. H., Kim, J. J. ,…, Ko, Y. H. (2022). Identification and characterization of cancer-associated fibroblast subpopulations in lung adenocarcinoma. Cancers, 14(14), 3486. https://doi.org/10.3390/cancers14143486

37.

Kieffer, Y., Hocine, H. R., Gentric, G., Pelon, F., Bernard, C., Bourachot, B. ,…, Mechta-Grigoriou, F. (2020). Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discovery, 10(9), 1330–1351. https://doi.org/10.1158/2159-8290.CD-19-1384

38.

Mosa, M. H., Michels, B. E., Menche, C., Nicolas, A. M., Darvishi, T., Greten, F. R., & Farin, H. F. (2020). A Wnt-induced phenotypic switch in cancer-associated fibroblasts inhibits EMT in colorectal cancer. Cancer Research, 80(24), 5569–5582. https://doi.org/10.1158/0008-5472.CAN-20-0263CrossRefPubMed

39.

Öhlund, D., Handly-Santana, A., Biffi, G., Elyada, E., Almeida, A. S., Ponz-Sarvise, M. ,…, Tuveson, D. A. (2017). Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. The Journal of Experimental Medicine, 214(3), 579–596. https://doi.org/10.1084/jem.20162024

40.

Chen, Z., Zhou, L., Liu, L., Hou, Y., Xiong, M., Yang, Y. ,…, Chen, K. (2020). Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. Nature Communications, 11(1), 5077. https://doi.org/10.1038/s41467-020-18916-5

41.

Affo, S., Nair, A., Brundu, F., Ravichandra, A., Bhattacharjee, S., Matsuda, M. ,…, Schwabe, R. F. (2021). Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell, 39(6), 866–882.e11. https://doi.org/10.1016/j.ccell.2021.03.012

42.

Biffi, G., Oni, T. E., Spielman, B., Hao, Y., Elyada, E., Park, Y. ,…, Tuveson, D. A. (2019). IL1-induced JAK/STAT signaling is antagonized by TGFβ to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discovery, 9(2), 282–301. https://doi.org/10.1158/2159-8290.CD-18-0710

43.

Zheng, S., Hu, C., Lin, H., Li, G., Xia, R., Zhang, X., … Chen, R. (2022). circCUL2 induces an inflammatory CAF phenotype in pancreatic ductal adenocarcinoma via the activation of the MyD88-dependent NF-κB signaling pathway. Journal of experimental & clinical cancer research: CR, 41(1), 71. https://doi.org/10.1186/s13046-021-02237-6

44.

Picard, F. S. R., Lutz, V., Brichkina, A., Neuhaus, F., Ruckenbrod, T., Hupfer, A. ,…, Huber, M. (2023). IL-17A-producing CD8+ T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts. Gut, gutjnl-2022–327855. https://doi.org/10.1136/gutjnl-2022-327855

45.

Fuentes, N. R., & Taniguchi, C. M. (2023). Turning down oxygen to turn up inflammation in CAFs. Cancer Research, 83(10), 1560–1562. https://doi.org/10.1158/0008-5472.CAN-23-0523CrossRefPubMed

46.

Schwörer, S., Cimino, F. V., Ros, M., Tsanov, K. M., Ng, C., Lowe, S. W. ,…, Thompson, C. B. (2023). Hypoxia potentiates the inflammatory fibroblast phenotype promoted by pancreatic cancer cell-derived cytokines. Cancer Research, 83(10), 1596–1610. https://doi.org/10.1158/0008-5472.CAN-22-2316

47.

Elyada, E., Bolisetty, M., Laise, P., Flynn, W. F., Courtois, E. T., Burkhart, R. A. ,…, Tuveson, D. A. (2019). Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discovery, 9(8), 1102–1123. https://doi.org/10.1158/2159-8290.CD-19-0094

48.

Wilson, R. B., Archid, R., & Reymond, M. A. (2020). Reprogramming of mesothelial-mesenchymal transition in chronic peritoneal diseases by estrogen receptor modulation and TGF-β1 inhibition. International Journal of Molecular Sciences, 21(11), 4158. https://doi.org/10.3390/ijms21114158CrossRefPubMedPubMedCentral

49.

apCAFs are derived from mesothelial cells and induce regulatory T cells. (2022). Cancer Discovery, 12(7), 1609. https://doi.org/10.1158/2159-8290.CD-RW2022-085

50.

Hu, B., Wu, C., Mao, H., Gu, H., Dong, H., Yan, J. ,…, Long, J. (2022). Subpopulations of cancer-associated fibroblasts link the prognosis and metabolic features of pancreatic ductal adenocarcinoma. Annals of Translational Medicine, 10(5), 262. https://doi.org/10.21037/atm-22-407

51.

Lavie, D., Ben-Shmuel, A., Erez, N., & Scherz-Shouval, R. (2022). Cancer-associated fibroblasts in the single-cell era. Nature Cancer, 3(7), 793–807. https://doi.org/10.1038/s43018-022-00411-zCrossRefPubMedPubMedCentral

52.

Nurmik, M., Ullmann, P., Rodriguez, F., Haan, S., & Letellier, E. (2020). In search of definitions: Cancer-associated fibroblasts and their markers. International Journal of Cancer, 146(4), 895–905. https://doi.org/10.1002/ijc.32193CrossRefPubMed

53.

Venning, F. A., Zornhagen, K. W., Wullkopf, L., Sjölund, J., Rodriguez-Cupello, C., Kjellman, P. ,…, Madsen, C. D. (2021). Deciphering the temporal heterogeneity of cancer-associated fibroblast subpopulations in breast cancer. Journal of experimental & clinical cancer research: CR, 40(1), 175. https://doi.org/10.1186/s13046-021-01944-4

54.

Weber, C. E., Kothari, A. N., Wai, P. Y., Li, N. Y., Driver, J., Zapf, M. A. C., & Mi, Z. (2015). Osteopontin mediates an MZF1-TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer. Oncogene, 34(37), 4821–4833. https://doi.org/10.1038/onc.2014.410CrossRefPubMed

55.

Zhao, L., Chen, J., Pang, Y., Fu, K., Shang, Q., Wu, H. ,…, Chen, H. (2022). Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review. Theranostics, 12(4), 1557–1569. https://doi.org/10.7150/thno.69475

56.

Sotgia, F., Martinez-Outschoorn, U. E., Howell, A., Pestell, R. G., Pavlides, S., & Lisanti, M. P. (2012). Caveolin-1 and cancer metabolism in the tumor microenvironment: Markers, models, and mechanisms. Annual Review of Pathology, 7, 423–467. https://doi.org/10.1146/annurev-pathol-011811-120856CrossRefPubMed

57.

Li, M., Wang, J., Wang, C., Xia, L., Xu, J., Xie, X., & Lu, W. (2020). Microenvironment remodeled by tumor and stromal cells elevates fibroblast-derived COL1A1 and facilitates ovarian cancer metastasis. Experimental Cell Research, 394(1), 112153. https://doi.org/10.1016/j.yexcr.2020.112153CrossRefPubMed

58.

Lin, T.-Y., Chan, H.-H., Chen, S.-H., Sarvagalla, S., Chen, P.-S., Coumar, M. S. ,…, Cheung, C. H. A. (2020). BIRC5/Survivin is a novel ATG12-ATG5 conjugate interactor and an autophagy-induced DNA damage suppressor in human cancer and mouse embryonic fibroblast cells. Autophagy, 16(7), 1296–1313. https://doi.org/10.1080/15548627.2019.1671643

59.

Lee, K.-W., Yeo, S.-Y., Sung, C. O., & Kim, S.-H. (2015). Twist1 is a key regulator of cancer-associated fibroblasts. Cancer Research, 75(1), 73–85. https://doi.org/10.1158/0008-5472.CAN-14-0350CrossRefPubMed

60.

Su, S., Chen, J., Yao, H., Liu, J., Yu, S., Lao, L. ,…, Song, E. (2018). CD10+GPR77+ cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness. Cell, 172(4), 841–856.e16. https://doi.org/10.1016/j.cell.2018.01.009

61.

James, A. W., Hindle, P., Murray, I. R., West, C. C., Tawonsawatruk, T., Shen, J. ,…, Soo, C. (2017). Pericytes for the treatment of orthopedic conditions. Pharmacology & Therapeutics, 171, 93–103. https://doi.org/10.1016/j.pharmthera.2016.08.003

62.

Sauzay, C., Voutetakis, K., Chatziioannou, A., Chevet, E., & Avril, T. (2019). CD90/Thy-1, a cancer-associated cell surface signaling molecule. Frontiers in Cell and Developmental Biology, 7, 66. https://doi.org/10.3389/fcell.2019.00066CrossRefPubMedPubMedCentral

63.

Krishnamurty, A. T., Shyer, J. A., Thai, M., Gandham, V., Buechler, M. B., Yang, Y. A. ,…, Turley, S. J. (2022). LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity. Nature, 611(7934), 148–154. https://doi.org/10.1038/s41586-022-05272-1

64.

Ni, W.-D., Yang, Z.-T., Cui, C.-A., Cui, Y., Fang, L.-Y., & Xuan, Y.-H. (2017). Tenascin-C is a potential cancer-associated fibroblasts marker and predicts poor prognosis in prostate cancer. Biochemical and Biophysical Research Communications, 486(3), 607–612. https://doi.org/10.1016/j.bbrc.2017.03.021CrossRefPubMed

65.

Werner, S., Lützkendorf, J., Müller, T., Müller, L. P., & Posern, G. (2019). MRTF-A controls myofibroblastic differentiation of human multipotent stromal cells and their tumour-supporting function in xenograft models. Scientific Reports, 9(1), 11725. https://doi.org/10.1038/s41598-019-48142-zCrossRefPubMedPubMedCentral

66.

Szot, C., Saha, S., Zhang, X. M., Zhu, Z., Hilton, M. B., Morris, K. ,…, St Croix, B. (2018). Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release. The Journal of Clinical Investigation, 128(7), 2927–2943. https://doi.org/10.1172/JCI120481

67.

Zeltz, C., Alam, J., Liu, H., Erusappan, P. M., Hoschuetzky, H., Molven, A. ,…, Gullberg, D. (2019). α11β1 integrin is induced in a subset of cancer-associated fibroblasts in desmoplastic tumor stroma and mediates in vitro cell migration. Cancers, 11(6), 765. https://doi.org/10.3390/cancers11060765

68.

Hwang, W. L., Jagadeesh, K. A., Guo, J. A., Hoffman, H. I., Yadollahpour, P., Reeves, J. W. ,…, Regev, A. (2022). Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. Nature Genetics, 54(8), 1178–1191. https://doi.org/10.1038/s41588-022-01134-8

69.

Aghamaliyev, U., Gaitantzi, H., Thomas, M., Simon-Keller, K., Gaiser, T., Marx, A. ,…, Breitkopf-Heinlein, K. (2019). Downregulation of SPARC is associated with epithelial-mesenchymal transition and low differentiation state of biliary tract cancer cells. European Surgical Research. Europaische Chirurgische Forschung. Recherches Chirurgicales Europeennes, 60(1–2), 1–12. https://doi.org/10.1159/000494734

70.

Silini, A., Ghilardi, C., Figini, S., Sangalli, F., Fruscio, R., Dahse, R. ,…, Bani, M. (2012). Regulator of G-protein signaling 5 (RGS5) protein: A novel marker of cancer vasculature elicited and sustained by the tumor’s proangiogenic microenvironment. Cellular and molecular life sciences: CMLS, 69(7), 1167–1178. https://doi.org/10.1007/s00018-011-0862-8

71.

Kan, T., Zhang, S., Zhou, S., Zhang, Y., Zhao, Y., Gao, Y. ,…, Yang, M. (2022). Single-cell RNA-seq recognized the initiator of epithelial ovarian cancer recurrence. Oncogene, 41(6), 895–906. https://doi.org/10.1038/s41388-021-02139-z

72.

Houthuijzen, J. M., de Bruijn, R., van der Burg, E., Drenth, A. P., Wientjens, E., Filipovic, T. ,…, Jonkers, J. (2023). CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer. Nature Communications, 14(1), 183. https://doi.org/10.1038/s41467-023-35793-w

73.

Daniel, S. K., Seo, Y. D., & Pillarisetty, V. G. (2020). The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies. Seminars in Cancer Biology, 65, 176–188. https://doi.org/10.1016/j.semcancer.2019.12.007CrossRefPubMed

74.

Neuzillet, C., Nicolle, R., Raffenne, J., Tijeras-Raballand, A., Brunel, A., Astorgues-Xerri, L. ,…, Bousquet, C. (2022). Periostin- and podoplanin-positive cancer-associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenocarcinoma. The Journal of Pathology, 258(4), 408–425. https://doi.org/10.1002/path.6011

75.

Su, H., Na, N., Zhang, X., & Zhao, Y. (2017). The biological function and significance of CD74 in immune diseases. Inflammation Research: Official Journal of the European Histamine Research Society ... [et Al.], 66(3), 209–216. https://doi.org/10.1007/s00011-016-0995-1

76.

Peran, I., Dakshanamurthy, S., McCoy, M. D., Mavropoulos, A., Allo, B., Sebastian, A. ,…, Byers, S. W. (2021). Cadherin 11 promotes immunosuppression and extracellular matrix deposition to support growth of pancreatic tumors and resistance to gemcitabine in mice. Gastroenterology, 160(4), 1359–1372.e13. https://doi.org/10.1053/j.gastro.2020.11.044

77.

Zawieracz, K., & Eckert, M. A. (2022). Isolation of normal and cancer-associated fibroblasts. In P. K. Kreeger (Ed.), Ovarian Cancer (Vol. 2424, pp. 155–165). New York, NY: Springer US. https://doi.org/10.1007/978-1-0716-1956-8_10

78.

Yasuda, T., Koiwa, M., Yonemura, A., Akiyama, T., Baba, H., & Ishimoto, T. (2021). Protocol to establish cancer-associated fibroblasts from surgically resected tissues and generate senescent fibroblasts. STAR protocols, 2(2), 100553. https://doi.org/10.1016/j.xpro.2021.100553CrossRefPubMedPubMedCentral

79.

Hu, H., Piotrowska, Z., Hare, P. J., Chen, H., Mulvey, H. E., Mayfield, A. ,…, Engelman, J. A. (2021). Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. Cancer Cell, 39(11), 1531–1547.e10. https://doi.org/10.1016/j.ccell.2021.09.003

80.

LeBleu, V. S., Taduri, G., O’Connell, J., Teng, Y., Cooke, V. G., Woda, C. ,…, Kalluri, R. (2013). Origin and function of myofibroblasts in kidney fibrosis. Nature Medicine, 19(8), 1047–1053. https://doi.org/10.1038/nm.3218

81.

Tang, X., Hou, Y., Yang, G., Wang, X., Tang, S., Du, Y.-E. ,…, Liu, M. (2016). Stromal miR-200s contribute to breast cancer cell invasion through CAF activation and ECM remodeling. Cell Death and Differentiation, 23(1), 132–145. https://doi.org/10.1038/cdd.2015.78

82.

Jain, S., Rick, J. W., Joshi, R. S., Beniwal, A., Spatz, J., Gill, S. ,…, Aghi, M. K. (2023). Single-cell RNA sequencing and spatial transcriptomics reveal cancer-associated fibroblasts in glioblastoma with protumoral effects. The Journal of Clinical Investigation, 133(5), e147087. https://doi.org/10.1172/JCI147087

83.

Foster, D. S., Januszyk, M., Delitto, D., Yost, K. E., Griffin, M., Guo, J. ,…, Longaker, M. T. (2022). Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin. Cancer Cell, 40(11), 1392–1406.e7. https://doi.org/10.1016/j.ccell.2022.09.015

84.

Dvořánková, B, Lacina, L, & Smetana, K (2019). Isolation of normal fibroblasts and their cancer-associated counterparts (CAFs) for biomedical research. Methods in Molecular Biology (Clifton, N.J.), 1879, 393–406 https://doi.org/10.1007/7651_2018_137

85.

Yoshida, G. J. (2020). Applications of patient-derived tumor xenograft models and tumor organoids. Journal of Hematology & Oncology, 13(1), 4. https://doi.org/10.1186/s13045-019-0829-zCrossRef

86.

Xu, H., Lyu, X., Yi, M., Zhao, W., Song, Y., & Wu, K. (2018). Organoid technology and applications in cancer research. Journal of Hematology & Oncology, 11(1), 116. https://doi.org/10.1186/s13045-018-0662-9CrossRef

87.

Tuveson, D, & Clevers, H (2019) Cancer modeling meets human organoid technology Science New York, NY, 364 6444, 952–955 https://doi.org/10.1126/science.aaw6985

88.

Zou, Z., Lin, Z., Wu, C., Tan, J., Zhang, J., Peng, Y. ,…, Zhang, Y. (2023). Micro-engineered organoid-on-a-chip based on mesenchymal stromal cells to predict immunotherapy responses of HCC patients. Advanced Science (Weinheim, Baden-Wurttemberg, Germany), 10(27), e2302640. https://doi.org/10.1002/advs.202302640

89.

Nassar, D., & Blanpain, C. (2016). Cancer stem cells: Basic concepts and therapeutic implications. Annual Review of Pathology, 11, 47–76. https://doi.org/10.1146/annurev-pathol-012615-044438CrossRefPubMed

90.

Feng, Y, Abdel Mouti, M, & Pauklin, S (2021) PAF1 Regulates the stemness of pancreatic cancer stem cells. Gastroenterology, 160 6, 2224–2225 https://doi.org/10.1053/j.gastro.2021.01.201

91.

Nallasamy, P., Nimmakayala, R. K., Karmakar, S., Leon, F., Seshacharyulu, P., Lakshmanan, I. ,…, Ponnusamy, M. P. (2021). Pancreatic tumor microenvironment factor promotes cancer stemness via SPP1-CD44 axis. Gastroenterology, 161(6), 1998–2013.e7. https://doi.org/10.1053/j.gastro.2021.08.023

92.

Wang, Y., Yu, H., Yu, M., Liu, H., Zhang, B., Wang, Y. ,…, Xia, Q. (2023). CD24 blockade as a novel strategy for cancer treatment. International Immunopharmacology, 121, 110557. https://doi.org/10.1016/j.intimp.2023.110557

93.

Pandey, S., Lee, M., Lim, J., Park, S., Choung, Y.-H., Kim, J. E. ,…, Chung, J. H. (2023). SMO-CRISPR-mediated apoptosis in CD133-targeted cancer stem cells and tumor growth inhibition. Journal of Controlled Release: Official Journal of the Controlled Release Society, 357, 94–108. https://doi.org/10.1016/j.jconrel.2023.03.023

94.

Zhao, R., He, B., Bie, Q., Cao, J., Lu, H., Zhang, Z. ,…, Zhang, B. (2022). AQP5 complements LGR5 to determine the fates of gastric cancer stem cells through regulating ULK1 ubiquitination. Journal of Experimental & Clinical Cancer Research: CR, 41(1), 322. https://doi.org/10.1186/s13046-022-02532-w

95.

Peng, H., Zhu, E., & Zhang, Y. (2022). Advances of cancer-associated fibroblasts in liver cancer. Biomarker Research, 10(1), 59. https://doi.org/10.1186/s40364-022-00406-zCrossRefPubMedPubMedCentral

96.

Ma, Z., Li, X., Mao, Y., Wei, C., Huang, Z., Li, G. ,…, Liu, Z. (2022). Interferon-dependent SLC14A1+ cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer. Cancer Cell, 40(12), 1550–1565.e7. https://doi.org/10.1016/j.ccell.2022.11.005

97.

Zhuang, J., Shen, L., Li, M., Sun, J., Hao, J., Li, J. ,…, Yan, J. (2023). Cancer-associated fibroblast-derived miR-146a-5p generates a niche that promotes bladder cancer stemness and chemoresistance. Cancer Research, 83(10), 1611–1627. https://doi.org/10.1158/0008-5472.CAN-22-2213

98.

Hu, J. L., Wang, W., Lan, X. L., Zeng, Z. C., Liang, Y. S., Yan, Y. R. ,…, Liang, L. (2019). CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer. Molecular Cancer, 18(1), 91. https://doi.org/10.1186/s12943-019-1019-x

99.

Lin, Y., Cai, Q., Chen, Y., Shi, T., Liu, W., Mao, L. ,…, He, R. (2022). CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase. Hepatology (Baltimore, Md.), 75(1), 28–42. https://doi.org/10.1002/hep.32099

100.

Katoh, M., & Katoh, M. (2022). WNT signaling and cancer stemness. Essays in Biochemistry, 66(4), 319–331. https://doi.org/10.1042/EBC20220016CrossRefPubMedPubMedCentral

101.

Avraamides, C. J., Garmy-Susini, B., & Varner, J. A. (2008). Integrins in angiogenesis and lymphangiogenesis. Nature Reviews. Cancer, 8(8), 604–617. https://doi.org/10.1038/nrc2353CrossRefPubMedPubMedCentral

102.

Chen, L., Endler, A., & Shibasaki, F. (2009). Hypoxia and angiogenesis: Regulation of hypoxia-inducible factors via novel binding factors. Experimental & Molecular Medicine, 41(12), 849–857. https://doi.org/10.3858/emm.2009.41.12.103CrossRef

103.

Baeriswyl, V., & Christofori, G. (2009). The angiogenic switch in carcinogenesis. Seminars in Cancer Biology, 19(5), 329–337. https://doi.org/10.1016/j.semcancer.2009.05.003CrossRefPubMed

104.

De Palma, M., Biziato, D., & Petrova, T. V. (2017). Microenvironmental regulation of tumour angiogenesis. Nature Reviews. Cancer, 17(8), 457–474. https://doi.org/10.1038/nrc.2017.51CrossRefPubMed

105.

Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R. ,…, Weinberg, R. A. (2005). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell, 121(3), 335–348. https://doi.org/10.1016/j.cell.2005.02.034

106.

Teicher, B. A., & Fricker, S. P. (2010). CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 16(11), 2927–2931. https://doi.org/10.1158/1078-0432.CCR-09-2329CrossRefPubMed

107.

Presta, M., Dell’Era, P., Mitola, S., Moroni, E., Ronca, R., & Rusnati, M. (2005). Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine & Growth Factor Reviews, 16(2), 159–178. https://doi.org/10.1016/j.cytogfr.2005.01.004CrossRef

108.

Papadopoulos, N., & Lennartsson, J. (2018). The PDGF/PDGFR pathway as a drug target. Molecular Aspects of Medicine, 62, 75–88. https://doi.org/10.1016/j.mam.2017.11.007CrossRefPubMed

109.

Crawford, Y., Kasman, I., Yu, L., Zhong, C., Wu, X., Modrusan, Z. ,…, Ferrara, N. (2009). PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell, 15(1), 21–34. https://doi.org/10.1016/j.ccr.2008.12.004

110.

Zhang, J.-Y., Zhu, W.-W., Wang, M.-Y., Zhai, R.-D., Wang, Q., Shen, W.-L., & Liu, L.-K. (2021). Cancer-associated fibroblasts promote oral squamous cell carcinoma progression through LOX-mediated matrix stiffness. Journal of Translational Medicine, 19(1), 513. https://doi.org/10.1186/s12967-021-03181-xCrossRefPubMedPubMedCentral

111.

Zhang, W., Zhang, S., Zhang, W., Yue, Y., Qian, W., & Wang, Z. (2021). Matrix stiffness and its influence on pancreatic diseases. Biochimica Et Biophysica Acta Reviews on Cancer, 1876(1), 188583. https://doi.org/10.1016/j.bbcan.2021.188583CrossRefPubMed

112.

Jiang, Y., Zhang, H., Wang, J., Liu, Y., Luo, T., & Hua, H. (2022). Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy. Journal of Hematology & Oncology, 15(1), 34. https://doi.org/10.1186/s13045-022-01252-0CrossRef

113.

Sack, K. D., Teran, M., & Nugent, M. A. (2016). Extracellular matrix stiffness controls vegf signaling and processing in endothelial cells. Journal of Cellular Physiology, 231(9), 2026–2039. https://doi.org/10.1002/jcp.25312CrossRefPubMed

114.

Li, M., Zhang, X., Wang, M., Wang, Y., Qian, J., Xing, X. ,…, Ren, Z. (2022). Activation of Piezo1 contributes to matrix stiffness-induced angiogenesis in hepatocellular carcinoma. Cancer Communications (London, England), 42(11), 1162–1184. https://doi.org/10.1002/cac2.12364

115.

Bao, M., Chen, Y., Liu, J.-T., Bao, H., Wang, W.-B., Qi, Y.-X., & Lv, F. (2022). Extracellular matrix stiffness controls VEGF165 secretion and neuroblastoma angiogenesis via the YAP/RUNX2/SRSF1 axis. Angiogenesis, 25(1), 71–86. https://doi.org/10.1007/s10456-021-09804-7CrossRefPubMed

116.

Kim, I., Choi, S., Yoo, S., Lee, M., & Kim, I.-S. (2022). Cancer-associated fibroblasts in the hypoxic tumor microenvironment. Cancers, 14(14), 3321. https://doi.org/10.3390/cancers14143321CrossRefPubMedPubMedCentral

117.

Kugeratski, F. G., Atkinson, S. J., Neilson, L. J., Lilla, S., Knight, J. R. P., Serneels, J. ,…, Zanivan, S. (2019). Hypoxic cancer-associated fibroblasts increase NCBP2-AS2/HIAR to promote endothelial sprouting through enhanced VEGF signaling. Science Signaling, 12(567), eaan8247. https://doi.org/10.1126/scisignal.aan8247

118.

Xu, H., Zhao, J., Li, J., Zhu, Z., Cui, Z., Liu, R. ,…, Xu, Q. (2022). Cancer associated fibroblast-derived CCL5 promotes hepatocellular carcinoma metastasis through activating HIF1α/ZEB1 axis. Cell Death & Disease, 13(5), 478. https://doi.org/10.1038/s41419-022-04935-1

119.

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011). Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science (New York, NY), 331(6024), 1565–1570 https://doi.org/10.1126/science.1203486

120.

O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019). Cancer immunoediting and resistance to T cell-based immunotherapy. Nature Reviews. Clinical Oncology, 16(3), 151–167. https://doi.org/10.1038/s41571-018-0142-8CrossRefPubMed

121.

Chen, C.-H., Seguin-Devaux, C., Burke, N. A., Oriss, T. B., Watkins, S. C., Clipstone, N., & Ray, A. (2003). Transforming growth factor beta blocks Tec kinase phosphorylation, Ca2+ influx, and NFATc translocation causing inhibition of T cell differentiation. The Journal of Experimental Medicine, 197(12), 1689–1699. https://doi.org/10.1084/jem.20021170CrossRefPubMedPubMedCentral

122.

Desbois, M., Udyavar, A. R., Ryner, L., Kozlowski, C., Guan, Y., Dürrbaum, M. ,…, Wang, Y. (2020). Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer. Nature Communications, 11(1), 5583. https://doi.org/10.1038/s41467-020-19408-2

123.

Batlle, E., & Massagué, J. (2019). Transforming growth factor-β signaling in immunity and cancer. Immunity, 50(4), 924–940. https://doi.org/10.1016/j.immuni.2019.03.024CrossRefPubMedPubMedCentral

124.

Ghahremanifard, P., Chanda, A., Bonni, S., & Bose, P. (2020). TGF-β mediated immune evasion in cancer-spotlight on cancer-associated fibroblasts. Cancers, 12(12), 3650. https://doi.org/10.3390/cancers12123650CrossRefPubMedPubMedCentral

125.

Correia, A. L., Guimaraes, J. C., Auf Der Maur, P., De Silva, D., Trefny, M. P., Okamoto, R. ,…, Bentires-Alj, M. (2021). Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy. Nature, 594(7864), 566–571. https://doi.org/10.1038/s41586-021-03614-z

126.

Ene–Obong, A., Clear, A. J., Watt, J., Wang, J., Fatah, R., Riches, J. C. ,…, Kocher, H. M. (2013). Activated pancreatic stellate cells sequester cd8+ t cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology, 145(5), 1121–1132. https://doi.org/10.1053/j.gastro.2013.07.025

127.

Li, X., Sun, Z., Peng, G., Xiao, Y., Guo, J., Wu, B. ,…, Wang, X. (2022). Single-cell RNA sequencing reveals a pro-invasive cancer-associated fibroblast subgroup associated with poor clinical outcomes in patients with gastric cancer. Theranostics, 12(2), 620–638. https://doi.org/10.7150/thno.60540

128.

Cheng, Y., Li, H., Deng, Y., Tai, Y., Zeng, K., Zhang, Y. ,…, Yang, Y. (2018). Cancer-associated fibroblasts induce PDL1+ neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma. Cell Death & Disease, 9(4), 422. https://doi.org/10.1038/s41419-018-0458-4

129.

Kato, T., Noma, K., Ohara, T., Kashima, H., Katsura, Y., Sato, H. ,…, Fujiwara, T. (2018). Cancer-associated fibroblasts affect intratumoral CD8+ and FoxP3+ T cells via IL6 in the tumor microenvironment. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 24(19), 4820–4833. https://doi.org/10.1158/1078-0432.CCR-18-0205

130.

Eskandari-Malayeri, F., & Rezaei, M. (2022). Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review. Frontiers in Immunology, 13, 996145. https://doi.org/10.3389/fimmu.2022.996145CrossRefPubMedPubMedCentral

131.

Warburg, O., Wind, F., & Negelein, E. (1927). The metabolism of tumors in the body. The Journal of General Physiology, 8(6), 519–530. https://doi.org/10.1085/jgp.8.6.519CrossRefPubMedPubMedCentral

132.

Liang, L., Li, W., Li, X., Jin, X., Liao, Q., Li, Y., & Zhou, Y. (2022). “Reverse Warburg effect” of cancer-associated fibroblasts (Review). International Journal of Oncology, 60(6), 67. https://doi.org/10.3892/ijo.2022.5357CrossRefPubMed

133.

Jaworska, M., Szczudło, J., Pietrzyk, A., Shah, J., Trojan, S. E., Ostrowska, B., & Kocemba-Pilarczyk, K. A. (2023). The Warburg effect: A score for many instruments in the concert of cancer and cancer niche cells. Pharmacological reports: PR. https://doi.org/10.1007/s43440-023-00504-1

134.

Mao, X., Wong, S. Y. S., Tse, E. Y. T., Ko, F. C. F., Tey, S. K., Yeung, Y. S. ,…, Yam, J. W. P. (2016). Mechanisms through which hypoxia-induced caveolin-1 drives tumorigenesis and metastasis in hepatocellular carcinoma. Cancer Research, 76(24), 7242–7253. https://doi.org/10.1158/0008-5472.CAN-16-1031

135.

Cruz-Bermúdez, A., Laza-Briviesca, R., Vicente-Blanco, R. J., García-Grande, A., Coronado, M. J., Laine-Menéndez, S. ,…, Provencio, M. (2019). Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling. Free Radical Biology & Medicine, 130, 163–173. https://doi.org/10.1016/j.freeradbiomed.2018.10.450

136.

Chen, X., & Song, E. (2019). Turning foes to friends: Targeting cancer-associated fibroblasts. Nature Reviews Drug Discovery, 18(2), 99–115. https://doi.org/10.1038/s41573-018-0004-1CrossRefPubMed

137.

Aiello, N. M., Brabletz, T., Kang, Y., Nieto, M. A., Weinberg, R. A., & Stanger, B. Z. (2017). Upholding a role for EMT in pancreatic cancer metastasis. Nature, 547(7661), E7–E8. https://doi.org/10.1038/nature22963CrossRefPubMedPubMedCentral

138.

Hao, Y., Baker, D., & Ten Dijke, P. (2019). TGF-β-mediated epithelial-mesenchymal transition and cancer metastasis. International Journal of Molecular Sciences, 20(11), 2767. https://doi.org/10.3390/ijms20112767CrossRefPubMedPubMedCentral

139.

Zhang, T., Li, X., He, Y., Wang, Y., Shen, J., Wang, S. ,…, Shen, L. (2022). Cancer-associated fibroblasts-derived HAPLN1 promotes tumour invasion through extracellular matrix remodeling in gastric cancer. Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 25(2), 346–359. https://doi.org/10.1007/s10120-021-01259-5

140.

Sakamoto, H., Koma, Y.-I., Higashino, N., Kodama, T., Tanigawa, K., Shimizu, M. ,…, Yokozaki, H. (2021). PAI-1 derived from cancer-associated fibroblasts in esophageal squamous cell carcinoma promotes the invasion of cancer cells and the migration of macrophages. Laboratory Investigation; a Journal of Technical Methods and Pathology, 101(3), 353–368. https://doi.org/10.1038/s41374-020-00512-2

141.

Sun, L.-P., Xu, K., Cui, J., Yuan, D.-Y., Zou, B., Li, J. ,…, Zhang, B. (2019). Cancer‑associated fibroblast‑derived exosomal miR‑382‑5p promotes the migration and invasion of oral squamous cell carcinoma. Oncology Reports, 42(4), 1319–1328. https://doi.org/10.3892/or.2019.7255

142.

Yan, Z., Sheng, Z., Zheng, Y., Feng, R., Xiao, Q., Shi, L. ,…, Zhang, B. (2021). Cancer-associated fibroblast-derived exosomal miR-18b promotes breast cancer invasion and metastasis by regulating TCEAL7. Cell Death & Disease, 12(12), 1120. https://doi.org/10.1038/s41419-021-04409-w

143.

Fattet, L., Jung, H.-Y., Matsumoto, M. W., Aubol, B. E., Kumar, A., Adams, J. A. ,…, Yang, J. (2020). Matrix rigidity controls epithelial-mesenchymal plasticity and tumor metastasis via a mechanoresponsive EPHA2/LYN complex. Developmental Cell, 54(3), 302–316.e7. https://doi.org/10.1016/j.devcel.2020.05.031

144.

Wei, S. C., Fattet, L., Tsai, J. H., Guo, Y., Pai, V. H., Majeski, H. E. ,…, Yang, J. (2015). Matrix stiffness drives epithelial-mesenchymal transition and tumour metastasis through a TWIST1-G3BP2 mechanotransduction pathway. Nature Cell Biology, 17(5), 678–688. https://doi.org/10.1038/ncb3157

145.

Labernadie, A., Kato, T., Brugués, A., Serra-Picamal, X., Derzsi, S., Arwert, E. ,…, Trepat, X. (2017). A mechanically active heterotypic E-cadherin/N-cadherin adhesion enables fibroblasts to drive cancer cell invasion. Nature Cell Biology, 19(3), 224–237. https://doi.org/10.1038/ncb3478

146.

Erdogan, B., Ao, M., White, L. M., Means, A. L., Brewer, B. M., Yang, L. ,…, Webb, D. J. (2017). Cancer-associated fibroblasts promote directional cancer cell migration by aligning fibronectin. The Journal of Cell Biology, 216(11), 3799–3816. https://doi.org/10.1083/jcb.201704053

147.

Sabeh, F., Ota, I., Holmbeck, K., Birkedal-Hansen, H., Soloway, P., Balbin, M. ,…, Weiss, S. J. (2004). Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. The Journal of Cell Biology, 167(4), 769–781. https://doi.org/10.1083/jcb.200408028

148.

Sobierajska, K., Ciszewski, W. M., Sacewicz-Hofman, I., & Niewiarowska, J. (2020). Endothelial cells in the tumor microenvironment. Advances in Experimental Medicine and Biology, 1234, 71–86. https://doi.org/10.1007/978-3-030-37184-5_6CrossRefPubMed

149.

Reymond, N., d’Água, B. B., & Ridley, A. J. (2013). Crossing the endothelial barrier during metastasis. Nature Reviews. Cancer, 13(12), 858–870. https://doi.org/10.1038/nrc3628CrossRefPubMed

150.

Wu, D., Deng, S., Li, L., Liu, T., Zhang, T., Li, J. ,…, Xu, Y. (2021). TGF-β1-mediated exosomal lnc-MMP2–2 increases blood-brain barrier permeability via the miRNA-1207–5p/EPB41L5 axis to promote non-small cell lung cancer brain metastasis. Cell Death & Disease, 12(8), 721. https://doi.org/10.1038/s41419-021-04004-z

151.

Gong, M. M., Lugo-Cintron, K. M., White, B. R., Kerr, S. C., Harari, P. M., & Beebe, D. J. (2019). Human organotypic lymphatic vessel model elucidates microenvironment-dependent signaling and barrier function. Biomaterials, 214, 119225. https://doi.org/10.1016/j.biomaterials.2019.119225CrossRefPubMedPubMedCentral

152.

Wei, W.-F., Chen, X.-J., Liang, L.-J., Yu, L., Wu, X.-G., Zhou, C.-F. ,…, Wang, W. (2021). Periostin+ cancer-associated fibroblasts promote lymph node metastasis by impairing the lymphatic endothelial barriers in cervical squamous cell carcinoma. Molecular Oncology, 15(1), 210–227. https://doi.org/10.1002/1878-0261.12837

153.

Tacconi, C., Correale, C., Gandelli, A., Spinelli, A., Dejana, E., D’Alessio, S., & Danese, S. (2015). Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion. Gastroenterology, 148(7), 1438-1451.e8. https://doi.org/10.1053/j.gastro.2015.03.005CrossRefPubMed

154.

Ao, Z., Shah, S. H., Machlin, L. M., Parajuli, R., Miller, P. C., Rawal, S. ,…, El-Ashry, D. (2015). Identification of cancer-associated fibroblasts in circulating blood from patients with metastatic breast cancer. Cancer Research, 75(22), 4681–4687. https://doi.org/10.1158/0008-5472.CAN-15-1633

155.

Sharma, U., Medina-Saenz, K., Miller, P. C., Troness, B., Spartz, A., Sandoval-Leon, A. ,…, El-Ashry, D. (2021). Heterotypic clustering of circulating tumor cells and circulating cancer-associated fibroblasts facilitates breast cancer metastasis. Breast Cancer Research and Treatment, 189(1), 63–80. https://doi.org/10.1007/s10549-021-06299-0

156.

Hurtado, P., Martínez-Pena, I., Yepes-Rodríguez, S., Bascoy-Otero, M., Abuín, C., Fernández-Santiago, C. ,…, Piñeiro, R. (2023). Modelling metastasis in zebrafish unveils regulatory interactions of cancer-associated fibroblasts with circulating tumour cells. Frontiers in Cell and Developmental Biology, 11, 1076432. https://doi.org/10.3389/fcell.2023.1076432

157.

Peinado, H., Zhang, H., Matei, I. R., Costa-Silva, B., Hoshino, A., Rodrigues, G. ,…, Lyden, D. (2017). Pre-metastatic niches: Organ-specific homes for metastases. Nature Reviews. Cancer, 17(5), 302–317. https://doi.org/10.1038/nrc.2017.6

158.

Zeng, H., Hou, Y., Zhou, X., Lang, L., Luo, H., Sun, Y. ,…, Liu, M. (2022). Cancer-associated fibroblasts facilitate premetastatic niche formation through lncRNA SNHG5-mediated angiogenesis and vascular permeability in breast cancer. Theranostics, 12(17), 7351–7370. https://doi.org/10.7150/thno.74753

159.

Kong, J., Tian, H., Zhang, F., Zhang, Z., Li, J., Liu, X. ,…, Liu, T. (2019). Extracellular vesicles of carcinoma-associated fibroblasts creates a pre-metastatic niche in the lung through activating fibroblasts. Molecular Cancer, 18(1), 175. https://doi.org/10.1186/s12943-019-1101-4

160.

Pein, M., Insua-Rodríguez, J., Hongu, T., Riedel, A., Meier, J., Wiedmann, L. ,…, Oskarsson, T. (2020). Metastasis-initiating cells induce and exploit a fibroblast niche to fuel malignant colonization of the lungs. Nature Communications, 11(1), 1494. https://doi.org/10.1038/s41467-020-15188-x

161.

Ji, Q., Zhou, L., Sui, H., Yang, L., Wu, X., Song, Q. ,…, Li, Q. (2020). Primary tumors release ITGBL1-rich extracellular vesicles to promote distal metastatic tumor growth through fibroblast-niche formation. Nature Communications, 11(1), 1211. https://doi.org/10.1038/s41467-020-14869-x

162.

Dong, G., Chen, P., Xu, Y., Liu, T., & Yin, R. (2023). Cancer-associated fibroblasts: Key criminals of tumor pre-metastatic niche. Cancer Letters, 566, 216234. https://doi.org/10.1016/j.canlet.2023.216234CrossRefPubMed

163.

Konieczkowski, D. J., Johannessen, C. M., & Garraway, L. A. (2018). A convergence-based framework for cancer drug resistance. Cancer Cell, 33(5), 801–815. https://doi.org/10.1016/j.ccell.2018.03.025CrossRefPubMedPubMedCentral

164.

Lu, Y., Jin, Z., Hou, J., Wu, X., Yu, Z., Yao, L. ,…, Su, L. (2023). Calponin 1 increases cancer-associated fibroblasts-mediated matrix stiffness to promote chemoresistance in gastric cancer. Matrix Biology: Journal of the International Society for Matrix Biology, 115, 1–15. https://doi.org/10.1016/j.matbio.2022.11.005

165.

Li, I., & Nabet, B. Y. (2019). Exosomes in the tumor microenvironment as mediators of cancer therapy resistance. Molecular Cancer, 18(1), 32. https://doi.org/10.1186/s12943-019-0975-5CrossRefPubMedPubMedCentral

166.

Uchihara, T., Miyake, K., Yonemura, A., Komohara, Y., Itoyama, R., Koiwa, M. ,…, Ishimoto, T. (2020). Extracellular vesicles from cancer-associated fibroblasts containing annexin A6 induces FAK-YAP activation by stabilizing β1 integrin, enhancing drug resistance. Cancer Research, 80(16), 3222–3235. https://doi.org/10.1158/0008-5472.CAN-19-3803

167.

Sansone, P., Savini, C., Kurelac, I., Chang, Q., Amato, L. B., Strillacci, A. ,…, Bromberg, J. (2017). Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy-resistant breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 114(43), E9066–E9075. https://doi.org/10.1073/pnas.1704862114

168.

Chen, X., Zhao, J., Herjan, T., Hong, L., Liao, Y., Liu, C. ,…, Li, X. (2022). IL-17-induced HIF1α drives resistance to anti-PD-L1 via fibroblast-mediated immune exclusion. The Journal of Experimental Medicine, 219(6), e20210693. https://doi.org/10.1084/jem.20210693

169.

Ostermann, E., Garin-Chesa, P., Heider, K. H., Kalat, M., Lamche, H., Puri, C. ,…, Adolf, G. R. (2008). Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 14(14), 4584–4592. https://doi.org/10.1158/1078-0432.CCR-07-5211

170.

Nicolas, A. M., Pesic, M., Engel, E., Ziegler, P. K., Diefenhardt, M., Kennel, K. B. ,…, Greten, F. R. (2022). Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. Cancer Cell, 40(2), 168–184.e13. https://doi.org/10.1016/j.ccell.2022.01.004

171.

Miyai, Y., Esaki, N., Takahashi, M., & Enomoto, A. (2020). Cancer-associated fibroblasts that restrain cancer progression: Hypotheses and perspectives. Cancer Science, 111(4), 1047–1057. https://doi.org/10.1111/cas.14346CrossRefPubMedPubMedCentral

172.

Mizutani, Y., Kobayashi, H., Iida, T., Asai, N., Masamune, A., Hara, A. ,…, Takahashi, M. (2019). Meflin-positive cancer-associated fibroblasts inhibit pancreatic carcinogenesis. Cancer Research, 79(20), 5367–5381. https://doi.org/10.1158/0008-5472.CAN-19-0454

173.

Bhattacharjee, S., Hamberger, F., Ravichandra, A., Miller, M., Nair, A., Affo, S. ,…, Schwabe, R. F. (2021). Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts. The Journal of Clinical Investigation, 131(11), e146987, 146987. https://doi.org/10.1172/JCI146987

174.

Chen, Y., Kim, J., Yang, S., Wang, H., Wu, C.-J., Sugimoto, H. ,…, Kalluri, R. (2021). Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer. Cancer Cell, 39(4), 548–565.e6. https://doi.org/10.1016/j.ccell.2021.02.007

175.

Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R. ,…, Kalluri, R. (2014). Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell, 25(6), 719–734. https://doi.org/10.1016/j.ccr.2014.04.005

176.

Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A. ,…, Stanger, B. Z. (2014). Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell, 25(6), 735–747. https://doi.org/10.1016/j.ccr.2014.04.021

177.

Mucciolo, G., Araos Henríquez, J., Jihad, M., Pinto Teles, S., Manansala, J. S., Li, W. ,…, Biffi, G. (2024). EGFR-activated myofibroblasts promote metastasis of pancreatic cancer. Cancer Cell, 42(1), 101–118.e11. https://doi.org/10.1016/j.ccell.2023.12.002

178.

Xiao, Y., & Yu, D. (2021). Tumor microenvironment as a therapeutic target in cancer. Pharmacology & Therapeutics, 221, 107753. https://doi.org/10.1016/j.pharmthera.2020.107753CrossRef

179.

Ford, K., Hanley, C. J., Mellone, M., Szyndralewiez, C., Heitz, F., Wiesel, P. ,…, Thomas, G. J. (2020). NOX4 inhibition potentiates immunotherapy by overcoming cancer-associated fibroblast-mediated CD8 T-cell Exclusion from tumors. Cancer Research, 80(9), 1846–1860. https://doi.org/10.1158/0008-5472.CAN-19-3158

180.

Hanley, C. J., Mellone, M., Ford, K., Thirdborough, S. M., Mellows, T., Frampton, S. J. ,…, Thomas, G. J. (2018). Targeting the myofibroblastic cancer-associated fibroblast phenotype through inhibition of NOX4. Journal of the National Cancer Institute, 110(1), 109–120. https://doi.org/10.1093/jnci/djx121

181.

Dominguez, C. X., Müller, S., Keerthivasan, S., Koeppen, H., Hung, J., Gierke, S. ,…, Turley, S. J. (2020). Single-cell RNA sequencing reveals stromal evolution into lrrc15+ myofibroblasts as a determinant of patient response to cancer immunotherapy. Cancer Discovery, 10(2), 232–253. https://doi.org/10.1158/2159-8290.CD-19-0644

182.

Demetri, G. D., Luke, J. J., Hollebecque, A., Powderly, J. D., Spira, A. I., Subbiah, V., … Villalobos, V. M. (2021). First-in-human phase I study of abbv-085, an antibody-drug conjugate targeting LRRC15, in sarcomas and other advanced solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 27(13), 3556–3566. https://doi.org/10.1158/1078-0432.CCR-20-4513

183.

Herbertz, S., Sawyer, J. S., Stauber, A. J., Gueorguieva, I., Driscoll, K. E., Estrem, S. T. ,…, Lahn, M. M. (2015). Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Design, Development and Therapy, 9, 4479–4499. https://doi.org/10.2147/DDDT.S86621

184.

van den Bulk, J., de Miranda, N. F. C. C., & Ten Dijke, P (2021). Therapeutic targeting of TGF-β in cancer: Hacking a master switch of immune suppression. Clinical Science (London, England: 1979), 135(1), 35–52 https://doi.org/10.1042/CS20201236

185.

Yamazaki, T., Gunderson, A. J., Gilchrist, M., Whiteford, M., Kiely, M. X., Hayman, A. ,…, Young, K. H. (2022). Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: A single-arm, phase 2 trial. The Lancet. Oncology, 23(9), 1189–1200. https://doi.org/10.1016/S1470-2045(22)00446-6

186.

Wei, Y., Kim, T. J., Peng, D. H., Duan, D., Gibbons, D. L., Yamauchi, M. ,…, Chapman, H. A. (2017). Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis. The Journal of Clinical Investigation, 127(10), 3675–3688. https://doi.org/10.1172/JCI94624

187.

Huang, H., Zhang, Y., Gallegos, V., Sorrelle, N., Zaid, M. M., Toombs, J. ,…, Brekken, R. A. (2019). Targeting TGFβR2-mutant tumors exposes vulnerabilities to stromal TGFβ blockade in pancreatic cancer. EMBO molecular medicine, 11(11), e10515. https://doi.org/10.15252/emmm.201910515

188.

Diwanji, R., O’Brien, N. A., Choi, J. E., Nguyen, B., Laszewski, T., Grauel, A. L. ,…, Jayaraman, P. (2023). Targeting the IL1β pathway for cancer immunotherapy remodels the tumor microenvironment and enhances antitumor immune responses. Cancer Immunology Research, 11(6), 777–791. https://doi.org/10.1158/2326-6066.CIR-22-0290

189.

Díaz-Maroto, N. G., Garcia-Vicién, G., Polcaro, G., Bañuls, M., Albert, N., Villanueva, A., & Molleví, D. G. (2021). The blockade of tumoral IL1β-mediated signaling in normal colonic fibroblasts sensitizes tumor cells to chemotherapy and prevents inflammatory CAF activation. International Journal of Molecular Sciences, 22(9), 4960. https://doi.org/10.3390/ijms22094960CrossRefPubMedPubMedCentral

190.

Cazet, A. S., Hui, M. N., Elsworth, B. L., Wu, S. Z., Roden, D., Chan, C.-L. ,…, Swarbrick, A. (2018). Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. Nature Communications, 9(1), 2897. https://doi.org/10.1038/s41467-018-05220-6

191.

Steele, N. G., Biffi, G., Kemp, S. B., Zhang, Y., Drouillard, D., Syu, L. ,…, Pasca di Magliano, M. (2021). Inhibition of hedgehog signaling alters fibroblast composition in pancreatic cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 27(7), 2023–2037. https://doi.org/10.1158/1078-0432.CCR-20-3715

192.

Zhao, J., Wang, H., Hsiao, C.-H., Chow, D. S.-L., Koay, E. J., Kang, Y., … Li, C. (2018). Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy. Biomaterials, 159, 215–228. https://doi.org/10.1016/j.biomaterials.2018.01.014

193.

Beauchamp, E. M., Ringer, L., Bulut, G., Sajwan, K. P., Hall, M. D., Lee, Y.-C. ,…, Uren, A. (2011). Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. The Journal of Clinical Investigation, 121(1), 148–160. https://doi.org/10.1172/JCI42874

194.

Slusarz, A., Shenouda, N. S., Sakla, M. S., Drenkhahn, S. K., Narula, A. S., MacDonald, R. S. ,…, Lubahn, D. B. (2010). Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer. Cancer Research, 70(8), 3382–3390. https://doi.org/10.1158/0008-5472.CAN-09-3012

195.

Chen, S., Nishi, M., Morine, Y., Shimada, M., Tokunaga, T., Kashihara, H. ,…, Wada, Y. (2022). Epigallocatechin‑3‑gallate hinders metabolic coupling to suppress colorectal cancer malignancy through targeting aerobic glycolysis in cancer‑associated fibroblasts. International Journal of Oncology, 60(2), 19. https://doi.org/10.3892/ijo.2022.5309

196.

Zhang, Q., Cao, W.-S., Wang, X.-Q., Zhang, M., Lu, X.-M., Chen, J.-Q. ,…, Han, H.-Y. (2019). Genistein inhibits nasopharyngeal cancer stem cells through sonic hedgehog signaling. Phytotherapy research: PTR, 33(10), 2783–2791. https://doi.org/10.1002/ptr.6464

197.

Chaudary, N., Pintilie, M., Hedley, D., Hill, R. P., Milosevic, M., & Mackay, H. (2017). Hedgehog inhibition enhances efficacy of radiation and cisplatin in orthotopic cervical cancer xenografts. British Journal of Cancer, 116(1), 50–57. https://doi.org/10.1038/bjc.2016.383CrossRefPubMed

198.

Hanley, C. J., & Thomas, G. J. (2020). T-cell tumour exclusion and immunotherapy resistance: A role for CAF targeting. British Journal of Cancer, 123(9), 1353–1355. https://doi.org/10.1038/s41416-020-1020-6CrossRefPubMedPubMedCentral

199.

Lang, L., & Teng, Y. (2019). Fibroblast Growth factor receptor 4 targeting in cancer: New insights into mechanisms and therapeutic strategies. Cells, 8(1), 31. https://doi.org/10.3390/cells8010031CrossRefPubMedPubMedCentral

200.

Zhang, M., Li, X., Wu, W., Gao, J., Han, Q., Sun, Z., & Zhao, R. C. (2022). Regorafenib Induces the apoptosis of gastrointestinal cancer-associated fibroblasts by inhibiting AKT phosphorylation. Stem Cells and Development, 31(13–14), 383–394. https://doi.org/10.1089/scd.2022.0088CrossRefPubMed

201.

Zhang, Z., Yu, W., Zheng, M., Liao, X., Wang, J., Yang, D. ,…, Lu, K. P. (2019). Pin1 inhibition potently suppresses gastric cancer growth and blocks PI3K/AKT and Wnt/β-catenin oncogenic pathways. Molecular Carcinogenesis, 58(8), 1450–1464. https://doi.org/10.1002/mc.23027

202.

Kitami, K., Yoshihara, M., Tamauchi, S., Sugiyama, M., Koya, Y., Yamakita, Y. ,…, Kajiyama, H. (2022). Peritoneal restoration by repurposing vitamin D inhibits ovarian cancer dissemination via blockade of the TGF-β1/thrombospondin-1 axis. Matrix Biology: Journal of the International Society for Matrix Biology, 109, 70–90. https://doi.org/10.1016/j.matbio.2022.03.003

203.

Santos, A. M., Jung, J., Aziz, N., Kissil, J. L., & Puré, E. (2009). Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. The Journal of Clinical Investigation, 119(12), 3613–3625. https://doi.org/10.1172/JCI38988CrossRefPubMedPubMedCentral

204.

Li, M., Li, G., Kiyokawa, J., Tirmizi, Z., Richardson, L. G., Ning, J. ,…, Wakimoto, H. (2020). Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma. Acta Neuropathologica Communications, 8(1), 221. https://doi.org/10.1186/s40478-020-01096-0

205.

Purcell, J. W., Tanlimco, S. G., Hickson, J., Fox, M., Sho, M., Durkin, L. ,…, Chao, D. T. (2018). LRRC15 is a novel mesenchymal protein and stromal target for antibody-drug conjugates. Cancer Research, 78(14), 4059–4072. https://doi.org/10.1158/0008-5472.CAN-18-0327

206.

Huang, T.-X., Tan, X.-Y., Huang, H.-S., Li, Y.-T., Liu, B.-L., Liu, K.-S. ,…, Fu, L. (2022). Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity. Gut, 71(2), 333–344. https://doi.org/10.1136/gutjnl-2020-322924

207.

Mellone, M., Piotrowska, K., Venturi, G., James, L., Bzura, A., Lopez, M. A. ,…, Thomas, G. J. (2022). ATM regulates differentiation of myofibroblastic cancer-associated fibroblasts and can be targeted to overcome immunotherapy Resistance. Cancer Research, 82(24), 4571–4585. https://doi.org/10.1158/0008-5472.CAN-22-0435

208.

Shen, Y., Wang, X., Lu, J., Salfenmoser, M., Wirsik, N. M., Schleussner, N. ,…, Schmidt, T. (2020). Reduction of liver metastasis stiffness improves response to bevacizumab in metastatic colorectal cancer. Cancer Cell, 37(6), 800–817.e7. https://doi.org/10.1016/j.ccell.2020.05.005

At a glance: The STEP trials

Springer Medicine

Cancer-associated fibroblasts: a versatile mediator in tumor progression, metastasis, and targeted therapy

Abstract

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Keynote webinar | Spotlight on antibody–drug conjugates in cancer